# US 2021/0330645 A1 · Antibacterial combinations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0330645 A1
- Document ID: US20210330645A1
- Status: Published application
- Kind: A1
- Application number: 17/274,115
- Filed: 2019-09-06
- Published: 2021-10-28
- Earliest claimed: 2018-09-07
- Applicants: Massey University
- Inventors: Jasna Rakonjac; Van Hung Vuong Le; Catrina Olivera; Raveen Weerasinghe; Julian Spagnuolo
- Web page: https://patentgrep.com/patent/US20210330645A1

## CPC

- A61K 31/4178: not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A01N 43/08: with oxygen as the ring hetero atom
- A01N 43/50: 1,3-Diazoles; Hydrogenated 1,3-diazoles
- A01N 43/76: 1,3-Oxazoles; Hydrogenated 1,3-oxazoles
- A01N 43/84: six-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,4
- A01N 45/00: Biocides, pest repellants or attractants, or plant growth regulators, containing compounds having three or more carbocyclic rings condensed among themselves, at least one ring not being a six-membered ring (halogenated hydrocarbons A01N29/08; condensed with heterocyclic rings A01N43/00)
- A01N 47/34: containing the groups [IMAGE cpc-sch-A01N-0947.gif], e.g. biuret; Thio analogues thereof; Urea-aldehyde condensation products
- A01P 1/00: Disinfectants; Antimicrobial compounds or mixtures thereof
- A61K 8/49: containing heterocyclic compounds
- A61K 8/4973: {with oxygen as the only hetero atom}
- A61K 8/63: Steroids; Derivatives thereof
- A61K 8/64: Proteins; Peptides; Derivatives or degradation products thereof
- A61K 31/345: Nitrofurans (nitrofurantoin A61K31/4178)
- A61K 31/422: not condensed and containing further heterocyclic rings
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/575: substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
- A61K 38/14: Peptides containing saccharide radicals; Derivatives thereof {, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin}
- A61P 31/04: Antibacterial agents
- A61Q 17/005: {Antimicrobial preparations}
- A61Q 19/00: Preparations for care of the skin
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A01N: PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF (preservation of food or foodstuff A23); BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES (preparations for medical, dental or toiletry purposes which kill or prevent the growth or proliferation of unwanted organisms A61K); PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01P: BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Disclosed herein are antibacterial combinations and compositions that are effective against Gram-negative bacteria. Also disclosed are uses of such combinations and compositions for inhibiting the growth and proliferation of Gram-negative bacteria and/or for killing Gram-negative bacteria and/or for treating a Gram-negative bacterial infection.

## Claims

### Claim 1

An antibacterial combination comprising a nitrofuran or a functional derivative or analogue thereof, and a bile salt or a functional derivative or analogue thereof.

### Claim 2 (depends on 1, 2)

The combination of claim 1 or claim 2, wherein the nitrofuran is selected from the group consisting of CM4, difurazone, furazolidone; nifurfoline, nifuroxazide, nifurquinazol, nifurtoinol, nifurzide, nitrofural (nitrofurazone), nitrofurantoin, ranbezolid and nifuratel, preferably wherein the nitrofuran is CM4, furazolidone or nitrofurantoin.

### Claim 3 (depends on 1, 2)

The combination of claim 1 or claim 2, wherein the bile salt or functional analogue or derivative thereof is selected from the group consisting of deoxycholate, cholate, chenodeoxycholate, taurocholate, glycocholate, taurochenodeoxycholate, glycochenodeoxycholate, lithocholate, and ursodeoxycholate.

### Claim 4 (depends on 1, 2, 3)

The combination of any one of claims 1 to 3, wherein the bile salt or functional analogue or derivative thereof is sodium deoxycholate (DOC).

### Claim 5 (depends on 1, 2, 3, 4)

The combination of any one of claims 1 to 4, further comprising a glycopeptide antibiotic.

### Claim 6 (depends on 5)

The combination of claim 5, wherein the glycopeptide antibiotic is vancomycin or a functional analogue or derivative thereof.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The combination of any one of claims 1 to 6 that inhibits the growth and/or proliferation of at least one Gram-negative bacterial species and/or that is bacteriostatic and or that is bactericidal for at least one Gram-negative bacterial species.

### Claim 8 (depends on 7)

The combination of claim 7, wherein the at least one Gram-negative bacterial species is a species of Enterobacteriaceae.

### Claim 9 (depends on 8)

The combination of claim 8, wherein the species of Enterobacteriaceae is selected from the group consisting of Escherichia spp., preferably E. coli; Salmonella spp., preferably S. enteritidis, S. infantis, S. dublin, S. typhimurium, S. paratyphi, S. schottmulleri, or S. choleraesuis; Citrobacter spp., preferably Citrobacter gillenii, Neisseria spp., preferably N. meningitis or N. gonorrhoeae; Acinetobacter spp.; Bacteroides spp., preferably B. fragilis; Bordetella spp., preferably B. pertussis or B. parapertussis; Brucella spp., preferably B. melitentis, B. abortus or B. suis; Campylobacter spp., preferably C. jejuni, C. coli or C. fetus; Enterobacter spp.; Haemophilus spp., preferably H. influenza or H. parainfluenzae; Legionella spp., preferably L. pneumophila; Pasteurella spp., preferably P. yersinia or P. multocida; Proteus spp., preferably P. mirabilis or P. vulgaris; Serratia spp., preferably S. marscences or S. liquifaciens; Shigella spp., preferably S. sonnei, S. flexneri, S. dysenteriae or S. boydii; Vibrio spp., preferably V. cholera or V. eltor; and Yersinia spp., preferably Y. enterolitica, Y. pseudotuberculosis or Y. pestis.

### Claim 10 (depends on 9)

The combination of claim 9, wherein the species of Enterobacteriaceae is selected from the group consisting of Escherichia coli, Salmonella enterica and Citrobacter gillenii or a strain thereof.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A composition comprising a combination of any one of claims 1 to 10 and a carrier, diluent or excipient.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

A pharmaceutical composition comprising a combination of any one of claims 1 to 10 or the composition of claim 11, and a pharmaceutically acceptable carrier, diluent or excipient.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

A cosmetic composition comprising a combination of any one of claims 1 to 10 or the composition of claim 11, and a cosmetically acceptable carrier, diluent or excipient.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

A method of inhibiting the growth and/or proliferation of at least one Gram-negative bacterial species and/or of killing at least one Gram-negative bacterial species comprising contacting the at least one Gram-negative bacterial species with the combination of any one of claims 1 to 10 or the composition of any one of claims 11 to 13.

### Claim 15 (depends on 14)

The method of claim 14 wherein contacting comprises contacting an object or part thereof that comprises the at least one Gram-negative bacterial species.

### Claim 16 (depends on 15)

The method of claim 15, wherein contacting is for a sufficient time to allow the combination or composition to inhibit the growth and/or proliferation of the at least one Gram-negative bacterial species on and/or in the object.

### Claim 17 (depends on 14, 15)

The method of claim 14 or claim 15, wherein the object is an inanimate object or part thereof, an animal or part thereof, or a plant or part thereof.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

A method of treating a bacterial infection, disease or condition comprising administering a combination of any one of claims 1 to 10 or the composition of claim 11 or 12 to subject in need thereof.

### Claim 19 (depends on 8, 9, 10, 18)

The method of claim 18, wherein the bacterial infection, disease and/or condition is caused by, or is associated with at least one Gram-negative bacterial species, preferably wherein the Gram negative bacterial species is as defined in any one of claims 8 to 10.

### Claim 20 (depends on 18, 19)

The method of claim 18 or 19, wherein the subject is an animal or part thereof, preferably a mammal, preferably a human.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

Use of a combination of any one of claims 1 to 10 or a composition of claim 11 in the manufacture of a medicament for treating a bacterial infection, disease or condition.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

Use of a combination of any one of claims 1 to 10 or the composition of claim 11 as a disinfectant.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

Use of a combination of any one of claims 1 to 10 or the composition claim 11 reduce or inhibit bacterial growth.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

Use of a combination of any one of claims 1 to 11 or the composition of claim 11 to make a cosmetic.
